A. TNBC accounts for over 50% of all breast cancer cases B. TNBC is more aggressive, has a higher rate of recurrence, and is associated with worse outcomes than other breast cancer subtypes C. TNBC is more commonly found in older white women D. TNBC rarely metastasizes to the lungs or brain E. Unsure

A. Fatigue, nausea, hand-foot syndrome, and myelosuppression B. Fatigue, nausea, diarrhea, and myelosuppression C. Fatigue, constipation, myelosuppression, and peripheral neuropathy D. Nausea, diarrhea, hyperglycemia, and peripheral neuropathy E. Unsure

A. Overall survival was significantly extended in the intent-to-treat (ITT) population, including both PD-L1–positive and –negative tumors B. In PD-L1–positive tumors, overall survival was approximately the same for atezolizumab + nab- paclitaxel and placebo + nab-paclitaxel C. The progression-free survival (PFS) benefit was observed in both PD-L1–positive and –negative tumors D. There was no clinical benefit with the addition of atezolizumab to nab-paclitaxel in PD-L1–negative tumors E. Unsure